Antigenic determinants of varicella virus
水痘病毒的抗原决定簇
基本信息
- 批准号:7074648
- 负责人:
- 金额:$ 36.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-09-01 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Varicella-zoster virus (VZV) is the cause of chickenpox and herpes zoster. VZV infection is a recurrent problem in both transplant and cancer patients. Herpes zoster and post herpetic neuralgia are also major medical problems in the elderly population. The VZV genome encodes about 70 open reading frames. The predominant VZV glycoprotein complex, in contrast to other alphaherpesviruses, is gE:gI. The long-term goal of this project is an in depth understanding of the role of VZV gE glycoprotein, an essential gene product which has many attributes of a cell surface receptor. For example, gE has endocytosis signals and both serine/threonine and tyrosine phosphorylation motifs in its cytoplasmic tail. The endocytosis of gE is clathrin mediated; subsequent gE trafficking is dependent on a casein kinase II phosphorylation sequence and the association of PACS-1. Analyses with a recombinant biologically active VZV ORF47 protein serine kinase led to the discovery that the viral kinase has a similar phosphorylation consensus motif to that of casein kinase II. Therefore, the hypothesis states that the ORF47 protein kinase and casein kinase II will act as team players to modify the acidic gE consensus site and in the process determine the gE trafficking pathways. The Specific Aims include the following: 1) Characterize the phosphorylation of gE by ORF47 kinase and document differences from casein kinase II phosphorylation, 2) Investigate the trafficking of gE in the presence and absence of ORF47 kinase, 3) Characterize the tyrosine phosphorylation sites on gE and the cellular site of tyrosine phosphorylation, and 4) Investigate the interaction of gI with gE during the phosphorylation and trafficking events, and the interaction of the gE:gl complex with PACS-l. Phosphorylation analyses will include both in vitro kinase assays and 2-D phosphopeptide gels. The trafficking experiments will include both transfection studies with wild type and mutant gE and gI glycoproteins, as well as infection studies with recombinant viruses containing mutated gE and ORF47 proteins. Endocytosis and trafficking data with labeled viral and cellular proteins will be analyzed by confocal microscopy followed by digital image analysis to obtain a pixel quantification. Preliminary data with wild type and mutant VZV suggested that gE trafficking was redirected in cells infected with an ORF47 mutant virus, namely, gE did not travel to the trans Golgi. Thus, this latter experiment provided strong evidence of an inter-relationship between virus-specific phosphorylation and directed trafficking of the gE glycoprotein. In turn, the cumulative data suggest that VZV gE trafficking occurs in two phosphorylation dependent pathways: one pathway not directed to the TGN may facilitate cell spread while the other pathway directed to the TGN may facilitate glycoprotein incorporation into virions. These proposed VZV studies will provide further insight into the multiple functions of gE and the gE:gI complex.
描述(由申请人提供):水痘带状疱疹病毒(VZV)是水痘和带状疱疹的病因。VZV感染在移植和癌症患者中都是一个反复出现的问题。带状疱疹和疱疹后神经痛也是老年人的主要医疗问题。VZV基因组编码大约70个开放阅读框。与其他甲型疱疹病毒相比,主要的VZV糖蛋白复合物是gE:gI。该项目的长期目标是深入了解VZV gE糖蛋白的作用,VZV gE糖蛋白是一种重要的基因产物,具有细胞表面受体的许多属性。例如,gE具有胞吞信号,其细胞质尾部同时存在丝氨酸/苏氨酸和酪氨酸磷酸化基序。gE的内吞作用是由网格蛋白介导的;随后的gE转运依赖于酪蛋白激酶II磷酸化序列和PACS-1的关联。用重组生物活性VZV ORF47蛋白丝氨酸激酶进行分析,发现该病毒激酶具有与酪蛋白激酶II相似的磷酸化共识基序。因此,该假设表明ORF47蛋白激酶和酪蛋白激酶II将作为团队成员来修饰酸性gE共识位点,并在此过程中确定gE运输途径。具体目标包括:1)表征ORF47激酶对gE的磷酸化,并记录与酪蛋白激酶II磷酸化的差异;2)研究ORF47激酶存在和不存在时gE的转运;3)表征gE上酪氨酸磷酸化位点和酪氨酸磷酸化的细胞位点;4)研究gI在磷酸化和转运事件中与gE的相互作用,以及gE:gl复合物与pacs - 1的相互作用。磷酸化分析将包括体外激酶测定和2-D磷酸肽凝胶。转运实验将包括野生型和突变型gE和gI糖蛋白的转染研究,以及含有突变gE和ORF47蛋白的重组病毒的感染研究。内吞作用和运输数据与标记的病毒和细胞蛋白将通过共聚焦显微镜分析,然后进行数字图像分析,以获得像素量化。野生型和突变型VZV的初步数据表明,在感染ORF47突变病毒的细胞中,gE的转运被重定向,即gE没有进入反式高尔基体。因此,后一项实验提供了强有力的证据,证明病毒特异性磷酸化与gE糖蛋白的定向运输之间存在相互关系。反过来,累积数据表明,VZV - gE转运发生在两个磷酸化依赖途径中:一个不指向TGN的途径可能促进细胞扩散,而另一个指向TGN的途径可能促进糖蛋白并入病毒粒子。这些拟议的VZV研究将进一步深入了解gE和gE:gI复合物的多种功能。
项目成果
期刊论文数量(86)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Immunoprecipitable polypeptides specified by varicella-zoster virus.
水痘带状疱疹病毒特异的免疫沉淀多肽。
- DOI:10.1016/0042-6822(82)90322-1
- 发表时间:1982
- 期刊:
- 影响因子:3.7
- 作者:Grose,C;Friedrichs,WE
- 通讯作者:Friedrichs,WE
Immunogenic glycoproteins of laboratory and vaccine strains of Varicella-Zoster virus.
水痘带状疱疹病毒实验室和疫苗株的免疫原性糖蛋白。
- DOI:10.1128/iai.31.3.1044-1053.1981
- 发表时间:1981
- 期刊:
- 影响因子:3.1
- 作者:Grose,C;Edmond,BJ;Friedrichs,WE
- 通讯作者:Friedrichs,WE
Computer modeling of prototypic and aberrant nucleocapsids of varicella-zoster virus.
水痘带状疱疹病毒原型和异常核衣壳的计算机建模。
- DOI:10.1006/viro.1995.0041
- 发表时间:1995
- 期刊:
- 影响因子:0
- 作者:Grose,C;Harson,R;Beck,S
- 通讯作者:Beck,S
Immunology of the varicella-zoster virus glycoproteins.
水痘带状疱疹病毒糖蛋白的免疫学。
- DOI:10.1093/infdis/157.5.877
- 发表时间:1988
- 期刊:
- 影响因子:0
- 作者:Grose,C;Litwin,V
- 通讯作者:Litwin,V
Varicella-zoster virus p32/p36 complex is present in both the viral capsid and the nuclear matrix of the infected cell.
水痘-带状疱疹病毒 p32/p36 复合物存在于受感染细胞的病毒衣壳和核基质中。
- DOI:10.1128/jvi.57.1.155-164.1986
- 发表时间:1986
- 期刊:
- 影响因子:5.4
- 作者:Friedrichs,WE;Grose,C
- 通讯作者:Grose,C
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles F. Grose其他文献
Charles F. Grose的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles F. Grose', 18)}}的其他基金
Wild-type allele found in varicella vaccine virus during severe herpes zoster
严重带状疱疹期间水痘疫苗病毒中发现野生型等位基因
- 批准号:
10038935 - 财政年份:2020
- 资助金额:
$ 36.01万 - 项目类别:
Autophagy and ER stress during varicella infection
水痘感染期间的自噬和内质网应激
- 批准号:
8427354 - 财政年份:2011
- 资助金额:
$ 36.01万 - 项目类别:
Autophagy and ER stress during varicella infection
水痘感染期间的自噬和内质网应激
- 批准号:
8232048 - 财政年份:2011
- 资助金额:
$ 36.01万 - 项目类别:
Autophagy and ER stress during varicella infection
水痘感染期间的自噬和内质网应激
- 批准号:
8803757 - 财政年份:2011
- 资助金额:
$ 36.01万 - 项目类别:
Autophagy and ER stress during varicella infection
水痘感染期间的自噬和内质网应激
- 批准号:
8101645 - 财政年份:2011
- 资助金额:
$ 36.01万 - 项目类别:
ACQUISITION OF HUMAN HERPES VIRUS-8 IN INFANCY
在婴儿期获得人类疱疹病毒 8
- 批准号:
7604837 - 财政年份:2007
- 资助金额:
$ 36.01万 - 项目类别:
IMMUNOSCANNING ELECTRON MICROSCOPY OF HERPES VIRUSES
疱疹病毒的免疫扫描电子显微镜
- 批准号:
6278480 - 财政年份:1998
- 资助金额:
$ 36.01万 - 项目类别:
IMMUNOSCANNING ELECTRON MICROSCOPY OF HERPES VIRUSES
疱疹病毒的免疫扫描电子显微镜
- 批准号:
6117285 - 财政年份:1998
- 资助金额:
$ 36.01万 - 项目类别:
DNA SEQUENCING--ITERATIVE STEPS BY PRODUCT REGENERATION
DNA 测序——产物再生的迭代步骤
- 批准号:
2889694 - 财政年份:1998
- 资助金额:
$ 36.01万 - 项目类别:
相似国自然基金
casein kinase I alpha在卵母细胞减数分裂成熟和克隆胚胎发育中对染色体分离作用的研究
- 批准号:31160243
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Computer-aided design and development of isoform selective inhibitors of Casein Kinase 1
酪蛋白激酶 1 异构体选择性抑制剂的计算机辅助设计和开发
- 批准号:
10629703 - 财政年份:2023
- 资助金额:
$ 36.01万 - 项目类别:
Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis
在真菌发病机制中靶向酪蛋白激酶 1 (CK1) 样激酶 Yck2
- 批准号:
10437100 - 财政年份:2022
- 资助金额:
$ 36.01万 - 项目类别:
Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis
在真菌发病机制中靶向酪蛋白激酶 1 (CK1) 样激酶 Yck2
- 批准号:
10595027 - 财政年份:2022
- 资助金额:
$ 36.01万 - 项目类别:
Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents
类固醇增强选择性酪蛋白激酶抑制剂:同类首创的新型吸入式抗哮喘药物
- 批准号:
nhmrc : 1137171 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Development Grants
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
开发用于治疗脑癌的新型酪蛋白激酶 1 抑制剂
- 批准号:
10531565 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers
开发用于治疗脑癌的新型酪蛋白激酶 1 抑制剂
- 批准号:
9698320 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
酪蛋白激酶-1-δ 在原发性和转移性乳腺癌中的治疗靶向
- 批准号:
10524031 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Targeting casein kinase 1-alpha for cancer therapy
靶向酪蛋白激酶 1-α 进行癌症治疗
- 批准号:
10553872 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents
类固醇增强选择性酪蛋白激酶抑制剂:同类首创的新型吸入式抗哮喘药物
- 批准号:
nhmrc : GNT1137171 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Development Grants
Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer
酪蛋白激酶-1-δ 在原发性和转移性乳腺癌中的治疗靶向
- 批准号:
9710619 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别: